4.62
-0.15 (-3.14%)
| Previous Close | 4.77 |
| Open | 4.68 |
| Volume | 121,720 |
| Avg. Volume (3M) | 317,667 |
| Market Cap | 195,354,384 |
| Price / Book | 6.53 |
| 52 Weeks Range | |
| Earnings Date | 12 Feb 2025 - 17 Feb 2025 |
| Diluted EPS (TTM) | -0.960 |
| Total Debt/Equity (MRQ) | 1.67% |
| Current Ratio (MRQ) | 3.00 |
| Operating Cash Flow (TTM) | -15.63 M |
| Levered Free Cash Flow (TTM) | -15.19 M |
| Return on Assets (TTM) | -90.68% |
| Return on Equity (TTM) | -332.67% |
Market Trend
| Short Term | Medium Term | ||
| Industry | Biotechnology (US) | Mixed | Bearish |
| Biotechnology (Global) | Mixed | Bearish | |
| Stock | TuHURA Biosciences, Inc. | Bearish | - |
AIStockmoo Score
| Analyst Consensus | -2.0 |
| Insider Activity | NA |
| Price Volatility | -2.0 |
| Technical Moving Averages | 0.0 |
| Technical Oscillators | -2.5 |
| Average | -1.63 |
|
TuHURA Biosciences Inc is a Phase 3 registration stage immuno-oncology company developing novel technologies to overcome resistance to cancer immunotherapy. The company's personalized cancer vaccine candidate, IFx-2.0, is designed to overcome primary resistance to checkpoint inhibitors. It is preparing to initiate a single randomized placebo-controlled Phase 3 registration trial of IFx-2.0 administered as an adjunctive therapy to Keytruda (pembrolizumab) in first-line treatment for advanced or metastatic Merkel Cell Carcinoma. |
|
| Sector | Healthcare |
| Industry | Biotechnology |
| % Held by Insiders | 41.96% |
| % Held by Institutions | 8.43% |
No data within this time range.
No data within this time range.
| Date | Type | Details |
|---|---|---|
| 20 Aug 2025 | Announcement | TuHURA Biosciences, Inc. to Present at the 27th Annual H.C. Wainwright Global Investment Conference |
| 14 Aug 2025 | Announcement | TuHURA Biosciences, Inc. Reports Second Quarter 2025 Financial Results and Provides a Corporate Update |
| 01 Jul 2025 | Announcement | TuHURA Biosciences, Inc. Announces Inclusion in the Russell 3000® and Russell 2000® Indexes |
| 30 Jun 2025 | Announcement | TuHURA Biosciences Completes Acquisition of Kineta |
| 24 Jun 2025 | Announcement | TuHURA Biosciences Initiates Its Phase 3 Accelerated Approval Trial of IFx-2.0 as an Adjunctive Therapy to Keytruda® (pembrolizumab) in First Line Treatment for Advanced or Metastatic Merkel Cell Carcinoma |
| 23 Jun 2025 | Announcement | TuHURA Biosciences, Inc. and Kineta, Inc. Stockholders Approve Proposed Merger and All Related Proposals |
The support, resistance and trendline levels presented has been generated by an artificial intelligence (AI) model and should be interpreted with caution.
Portfolio
| Realized Profit | - |
| Unrealized Profit | - |
| Dividend Received 2025 | - |
| Total Profit | - |
| Avg. Return | - |
| Quantity (Buy) | - |
| Avg. Price (Buy) | - |
| Quantity (Sold) | - |
| Avg. Price (Sold) | - |